How to standardize and optimize the clinical practice pattern to improve diagnosis and treatment of age-related macular degeneration: interpretation of the Age-Related Macular Degeneration Guidelines of Royal College of Ophthalmologists
- Author:
- No author available
- Journal Title:
- Chinese Journal of Ocular Fundus Diseases
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1005-1015.2012.05.002
- Key Word:
- 黄斑变性/诊断;黄斑变性/治疗;脉络膜新生血管化/药物疗法;抗体,单克隆/治疗应用;述评;Macular degeneration/diagnosis;Macular degeneration/therapy;Choroidal neovascularization/drug therapy;Antibodies,monoclonal/therapeutic use;Editorial
Abstract： The diagnosis and treatment of age-related macular degeneration (AMD) is an international hotspot of eye research.Successful clinical applications of anti-VEGF drugs promoted both basic research and clinical practice of AMD.A number of countries and professional societies have established clinical guidelines for AMD management,including the epidemiology,risk factors,diagnosis,classification,and treatment process.These AMD guidelines are mostly based on recently published results of clinical trials,provided good model of evidence based medicine.It is urgent and necessary to have our own guideline which is suitable for Chinese patients.Reviewing and learning existed guidelines will help us to improve the clinical practice of AMD in China.
- [1]U, Schmidt-Erfurth,J W, Miller,M, Sickenberg,etc.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.[J].1999,117.
- [2]Neelam K,Nolan J,Beatty S,etc.Psychophysical function in age-related maculopathy.[J].2009,54(2).
- [3]Regillo CD,Schneider S,Ianchulev T,etc.Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.[J].2008,145(2).
- [4]Miller,JW,Schmidt,Erfurth-U,Sickenberg,M,etc.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study (comment) (see comments)[J].1999,117(9).
- [5]N M, Bressler.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.[J].2001,119(2).
- [6]Takeuchi K,Kachi S,Terasaki H,etc.Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration.[J].2012,26(1).
- [7]A.C. Bird,N.M. Bressler,S.B. Bressler,etc.An international classification and grading system for age-related maculopathy and age-related macular degeneration[J].1995,39(5).
- [8]Tomany SC,Klein BE,Meuer SM,etc.Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.[J].2002,109(10).
- [9]Tarita-Nistor,L.,Brent,M.H.,Steinbach,M.J.,etc.Fixation patterns in maculopathy: From binocular to monocular viewing[J].2012,89(3).
- [10]Mitchell P,Korobelnik JF,Lanzetta.Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.[J].2010,94(1).
- [11]Brown DM,Chung CY,Kim RY,etc.Ranibizumab for neovascular age-related macular degeneration.[J].2006,355(14).
- [12]R, Klein,M D, Davis,Y L, Magli,etc.The Wisconsin age-related maculopathy grading system.[J].1991,98(7).
- [13]Sy JP,Schneider S,Brown DM,etc.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.[J].2006,355(14).
- [14].Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin[J].1999.
- [15]Neil M, Bressler,Tom S, Chang,Ivan J, Su?er,etc.Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.[J].2010,117(4).